NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
360 DigiTech, Inc. (NASDAQ: QFIN)
CONTACT JAKUBOWITZ ABOUT QFIN:
https://claimyourloss.com/securities/360-digitech-inc-loss-submission-form/?id=19532&from=1
Class Period: April 29, 2021 - July 7, 2021
Lead Plaintiff Deadline: September 13, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Yalla Group Limited (NYSE:YALA)
CONTACT JAKUBOWITZ ABOUT YALA:
https://claimyourloss.com/securities/yalla-group-limited-loss-submission-form/?id=19532&from=1
Class Period: September 30, 2020 - August 9, 2021
Lead Plaintiff Deadline: October 12, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company overstated its user metrics and revenue and, as a result, the Company's public statements were materially false and misleading at all relevant times.
Sesen Bio, Inc. (NASDAQ:SESN)
CONTACT JAKUBOWITZ ABOUT SESN:
https://claimyourloss.com/securities/sesen-bio-inc-loss-submission-form/?id=19532&from=1
Class Period: December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline: October 18, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/663740/Lawsuits-Filed-Against-QFIN-YALA-and-SESN--Jakubowitz-Law-Pursues-Shareholders-Claims
